Thanks to its advanced technology, Genefill dermal fillers have one of the lowest residual BDDE particles in their composition, presenting a toxicity level lower than the more strictest standards around the world.
FDA allowed amount of Residual BDDE (EU) less than 0.0002 mg
Standards Amount of Residual BDDE (Genefill) less than 0.0001 mg
Having significantly lower toxicity has successfully demonstrated BDDE as one of the safest cross-linking agents to stabilize the HA-based dermal fillers in the industry.
Additionally, BDDE is also biodegradable making it much preferred for biomedical applications, especially cosmetic products.
*Disclaimer: Before any dermal filler treatment, we recommend asking your doctor about the product, crosslinking agents, and toxicity level.